Millennium Management
MRTX

Millennium Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Millennium Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$1.08M – 6733
2023
Q2 		$1.08M Sell
30,000
-10,400
-26% -$428K ﹤0.01% 3983
2023
Q1 		$1.5M Buy
40,400
+29,500
+271% +$1.33M ﹤0.01% 3711
2022
Q4 		$494K Buy
+10,900
New +$705K ﹤0.01% 4755
2022
Q3 		– Sell
-20,000
Closed -$1.34M – 7645
2022
Q2 		$1.34M Buy
+20,000
New +$1.27M ﹤0.01% 4099
2021
Q1 		– Sell
-10,000
Closed -$2.2M – 6624
2020
Q4 		$2.2M Buy
10,000
+2,000
+25% +$432K ﹤0.01% 3168
2020
Q3 		$1.33K Buy
+8,000
New +$1.09M ﹤0.01% 2929
2020
Q1 		– Sell
-25,000
Closed -$3.22M – 4671
2019
Q4 		$3.22M Sell
25,000
-125,000
-83% -$12.1M ﹤0.01% 2273
2019
Q3 		$11.7M Buy
+150,000
New +$14.1M 0.02% 1177
2019
Q2 		– Sell
-65,000
Closed -$4.76M – 4588
2019
Q1 		$4.76M Buy
+65,000
New +$4.42M 0.01% 1801
2018
Q3 		– Sell
-9,200
Closed -$454K – 4372
2018
Q2 		$454K Buy
+9,200
New +$347K ﹤0.01% 3205

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Millennium Management's MRTX Position: Q1 2024 in Review

Millennium Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 58,626 shares — an estimated $3.44M sold.

Millennium Management first reported a position in MRTX in Q3 2015 and held it in 29 quarters. The position peaked at $79.5M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Millennium Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Millennium Management sold 58,626 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.44M.
  • Millennium Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 29 quarters.
  • Millennium Management's Mirati Therapeutics, Inc. Common Stock position peaked at $79.5M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.